Lexicon Pharmaceuticals shares fall 1.59% in after-hours as FDA reviews sotagliflozin NDA for type 1 diabetes and chronic kidney disease treatment.

Lexicon Pharmaceuticals, Inc. fell 1.59% in after-hours trading, as the FDA is reviewing the company's NDA for sotagliflozin to treat type 1 diabetes and chronic kidney disease, with a decision expected by December 20, 2024. Additionally, the company began selling INPEFA® sotagliflozin in the U.S. in June 2023 to reduce the risk of cardiovascular death and heart failure hospitalization.